BSX
Another win for the heart-device aisle
Boston Scientific says its investigational SEISMIQ 4CE coronary intravascular lithotripsy catheter cleared a pretty important hurdle: the pivotal trial met both of its primary goals in patients with severely calcified coronary artery disease.
That matters because calcified arteries are the kind of problem that makes stent placement act like trying to renovate a house through the mail slot. If the device works as advertised, it could become a useful tool for doctors prepping vessels before stent implantation.
The numbers are doing the talking
The company said the study enrolled 420 patients. Here’s the headline math:
- 93.3% freedom from major adverse cardiac events at 30 days, beating the pre-set 86.2% bar
- 93.7% procedural success, ahead of the 85.8% target
- Stents were delivered successfully in all treated patients
- Residual stenosis stayed below 50%
Translation: the device didn’t just show up, it showed out.
Why investors should care
Boston Scientific has been leaning hard into devices that help doctors do more complex procedures, and this one fits that playbook neatly. The SEISMIQ 4CE catheter also uses the same console as the company’s peripheral artery disease system, which already got FDA clearance in 2025, so this isn’t some random science-fair prototype.
If the company can turn this into a commercial win, it adds another brick to the wall in a business where clinical credibility is basically currency.
Big picture: positive trial data doesn’t guarantee a straight path to sales, but it does make Boston Scientific’s heart portfolio look a little more robust—and Wall Street loves a good “we may have another product here” story.